183 related articles for article (PubMed ID: 28888217)
1. Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management.
Monjazeb S; Wilson J
Skin Therapy Lett; 2017 Sep; 22(5):5-7. PubMed ID: 28888217
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
3. Nursing Management of Cutaneous Toxicities From Epidermal Growth Factor Receptor Inhibitors.
Wallner M; Köck-Hódi S; Booze S; White KJ; Mayer H
Clin J Oncol Nurs; 2016 Oct; 20(5):529-36. PubMed ID: 27668373
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous drug eruptions associated with the use of new oncological drugs.
Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
[TBL] [Abstract][Full Text] [Related]
5. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy.
Fox LP
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):26-34. PubMed ID: 16736980
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors.
Lupu I; Voiculescu VM; Bacalbasa N; Prie BE; Cojocaru I; Giurcaneanu C
J Med Life; 2015; 8 Spec Issue(Spec Issue):57-61. PubMed ID: 26361513
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
[TBL] [Abstract][Full Text] [Related]
8. Targeting the epidermal growth factor receptor in solid tumors: focus on safety.
Lucchini E; Pilotto S; Spada E; Melisi D; Bria E; Tortora G
Expert Opin Drug Saf; 2014 May; 13(5):535-49. PubMed ID: 24684184
[TBL] [Abstract][Full Text] [Related]
9. Clinical management of EGFRI dermatologic toxicities: US perspective.
Lacouture ME; Cotliar J; Mitchell EP
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):17-21. PubMed ID: 18154214
[TBL] [Abstract][Full Text] [Related]
10. The Most Common Cutaneous Side Effects of Epidermal Growth Factor Receptor Inhibitors and Their Management.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2015; 23(4):282-8. PubMed ID: 26724881
[TBL] [Abstract][Full Text] [Related]
11. Mitigation of epidermal growth factor receptor inhibitor-induced side effects utilizing melanin and vascular-specific lasers: A case report series.
Kuo KY; Kwong B; Rahman Z
J Cosmet Laser Ther; 2017 Oct; 19(5):300-302. PubMed ID: 28463045
[TBL] [Abstract][Full Text] [Related]
12. Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors.
Boucher J; Olson L; Piperdi B
Clin J Oncol Nurs; 2011 Oct; 15(5):501-8. PubMed ID: 21951736
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
[TBL] [Abstract][Full Text] [Related]
14. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous reactions to epidermal growth factor receptor inhibitors.
Pomerantz RG; Mirvish ED; Geskin LJ
J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
[TBL] [Abstract][Full Text] [Related]
16. Advances in the management of cutaneous toxicities of targeted therapies.
Robert C; Sibaud V; Mateus C; Cherpelis BS
Semin Oncol; 2012 Apr; 39(2):227-40. PubMed ID: 22484194
[TBL] [Abstract][Full Text] [Related]
17. [Skin toxicities and unmet supportive care needs of patients with cancer undergoing EGFR-inhibitor therapy].
Matzka M; Stöhr D; Colditz A; Köck-Hódi S; Koller M; Mayer H
Pflege; 2017 Jan; 30(1):9-17. PubMed ID: 27901405
[TBL] [Abstract][Full Text] [Related]
18. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician.
Gutzmer R; Becker JC; Enk A; Garbe C; Hauschild A; Leverkus M; Reimer G; Treudler R; Tsianakas A; Ulrich C; Wollenberg A; Homey B
J Dtsch Dermatol Ges; 2011 Mar; 9(3):195-203. PubMed ID: 21059173
[TBL] [Abstract][Full Text] [Related]
19. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.
Fischer A; Rosen AC; Ensslin CJ; Wu S; Lacouture ME
Dermatol Ther; 2013; 26(2):135-48. PubMed ID: 23551370
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.
Hu JC; Sadeghi P; Pinter-Brown LC; Yashar S; Chiu MW
J Am Acad Dermatol; 2007 Feb; 56(2):317-26. PubMed ID: 17141360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]